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1. Introduction 
Down syndrome (DS) arises from triplication of genes on chromosome 21 (HSA21) and is 
characterized by neurological complications including cognitive dysfunction, epilepsy, and 
early onset Alzheimer’s disease (AD). At the histological and cellular level, DS brains show 
prolongation in the cell cycle length of neural progenitors, increased oxidative stress, and 
mitochondrial dysfunction. These pathological processes likely contribute to the observed 
decrease in neurogenesis, increased neuronal cell death, enhanced gliosis in the cortex, and a 
corresponding decrease in both neuronal glutamatergic and GABAergic expression. 
With recent advances in molecular biology and human genetics, many HSA21 genes have 
been identified, putative functions assigned to these genes and network analyses used to 
predict interconnecting, functional gene pathways. Interactions at this level are further 
complicated by gene regulatory mechanisms such as DNA methylation, histone acetylation 
and microRNA. In this respect, the neurological phenotypes seen in DS are not merely due 
to genomic imbalance from triplication of HSA21 genes, but also additive effects due to 
influences on associated genes within a given network or pathway and modification of gene 
expression due to epigenetic factors. 
The development of stem cell technologies has provided the opportunity to isolate human 
neural progenitors (HNPs) and induced pluripotent stem cells (iPS) from patients with 
known neurological disorders. These reagents are also used as tools to study molecular 
mechanisms and pharmacological therapies in various human diseases. They provide a 
means by which an understanding is established for interactions between various genes 
causal for a human disorder, especially in contiguous gene syndromes that are difficult to 
faithfully replicate in animal models. We have focused on the study of DS HNPs in relation 
to neurological phenotypes in the early onset of DS in these individuals. 
In the current review, we summarize the approaches taken, recent progress and insights 
gained from studies of DS during neural development, incorporating insights gained from 
the use of human DS neural progenitors.  
2. Down syndrome phenotype and genotype during neurodevelopment 
The most prominent neurological phenotypes in DS include mental retardation (MR), 
epilepsy, and dementia (early onset AD). Individuals with DS generally have mild to 
moderate MR with average intelligence quotient (IQ) among children at 50, as compared 
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with normal children at an IQ of 100. Children with DS generally exhibit better visual motor 
skills (such as drawing) than auditory and linguistic skills, which typically lead to a delay in 
language skill development. MR can also be accompanied by behavioural issues such as 
attention-deficit disorder (sometimes with hyperactivity) and autistic behaviour, especially 
in those with severe intellectual disability. The onset of seizures tends to occur in a bimodal 
distribution. At early ages, individuals with DS are susceptible to infantile spasms and tonic 
clonic seizures with myoclonus. These epilepsies are associated with MR and likely due to 
early impairments in brain development. Individuals with DS in the third decade of life are 
more prone to developing simple partial or complex partial seizures in addition to tonic-
clonic seizures. These focal epilepsies are likely associated with the increasing burden of 
parenchymal damage sustained from the progressive neuronal degeneration. It is estimated 
that 46% of Down's patients over the age of 50 have a diagnosis of epilepsy. Finally, AD is 
generally considered a neurodegenerative disorder that affects the elderly at 60 years of age 
and over. Premature AD is seen in DS in the early 40s (Arya et al., 2011; Contestabile et al., 
2010; Lott and Dierssen, 2010; Menendez, 2005) 
The clinical phenotypes in DS correlate with functional changes seen at the histological and 
cellular levels in DS brain. DS cortex shows increased simplified gyral patterning and 
delayed myelination (Banik et al., 1975; Cragg, 1975; Koo et al., 1992; Wisniewski, 1990; 
Wisniewski and Schmidt-Sidor, 1989). Neuronal loss has been seen in DS brain both during 
development, following differentiation and aging (Becker et al., 1991; Benda, 1947; Colon, 
1972; Davidoff, 1928; Golden and Hyman, 1994; Guidi et al., 2008; Ross et al., 1984; 
Wisniewski et al., 1984). Histological evidence of neurofibrillary plaques and tangles can be 
seen in the DS brain, consistent with the premature onset of AD (Motte and Williams, 1989). 
Changes in dendritic branching as well as neurotransmitter levels have also been reported 
in the DS brain tissue and likely correlate with the behavioural and cognitive difficulties 
seen in these individuals (Reynolds and Warner, 1988; Ross et al., 1984). At the cellular level, 
DS progenitors have prolonged cell cycle lengths, thereby impairing neurogenesis 
(Chakrabarti et al., 2007; Contestabile et al., 2007; Guidi et al., 2008). Neuronal numbers 
further decline presumably through increased levels of reactive oxygen  species (ROS), 
mitochondrial dysfunction and increased cell death in mature neurons (Busciglio et al., 2002; 
Guidi et al., 2008; Seidl et al., 2001). Following differentiation, neurons also show an 
imbalance of excitatory-inhibitory neurotransmission (Bhattacharyya et al., 2009), with 
reduced dendritic branching and spine density (Benavides-Piccione et al., 2004). Overall, 
these changes could all contribute to the MR, epilepsy and AD phenotypes seen in DS.  
Various neurological features in DS have been attributed to over-expression of individual 
genes on HSA21, and several of these genes might contribute to a final common pathway. For 
example, APP has been shown to promote neuronal degeneration and oxidative stress. Similar 
functions have been implicated in other HSA21 genes including BACH1, SOD1, and S100B, 
raising a possible role in AD.  Other HSA21 genes (TIAM1, SYNJ1, ITSN1, DSCR1) have been 
associated with synaptic dysfunction (suggestive of a pathological role in MR and epilepsy). 
Individual HSA21 genes with proposed neurological functions are summarized in Table 1. 
3. Identification of genes and pathways responsible for AD or MR 
Although HSA21 is a relatively small chromosome and single candidate genes have been 
shown to mimic certain DS features, the combinatorial effects of contiguous genes on  
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HSA21 
genes 
Downstream 
targets 
Endophenotype Exophenotype Ref 
NRIP1  Inhibit estrogen and 
glucocorticoid receptors 
 (Cavailles et al., 1995; 
Gardiner and Costa, 
2006; Subramaniam et 
al., 1999; Teyssier et al., 
2003)
APP Ptch1/smo 
Tau 
RAGE 
Tau 
IL6/gp130 
Notch 
MAP kinases 
Abeta deposition, 
astocytosis, microgliosis, 
neuronal loss, 
hyperphosphorylation 
Tau, decreased 
proliferation, increased cell 
death, mitochondrial 
dysfunction 
Dementia, 
learning and 
memory 
deficits  
(Abramov et al., 2004; 
Arancio et al., 2004; 
Harris-Cerruti et al., 
2004; Howlett and 
Richardson, 2009; 
Korbel et al., 2009; 
Kwak et al., 2010; 
Kwak et al., 2011; Mori 
et al., 2010; Prasher et 
al., 1998; Rovelet-
Lecrux et al., 2006; 
Takuma et al., 2009; 
Trazzi et al.) 
BACH1  Increase ROS  (Ferrando-Miguel et al., 
2003; Shim et al., 2003) 
TIAM1 RAC, NMDAR 
EphBR 
Altered neurite formation, 
abnormal dendrite spines 
 (Matsuo et al., 2002; 
Siddiqui et al., 2008; 
Tolias et al., 2005; 
Tolias et al., 2007) 
SOD1 APP Increase ROS, 
mitochondrial dysfunction
Learning and 
memory 
deficits  
(Furuta et al., 1995; 
Harris-Cerruti et al., 
2004; Iannello et al., 
1999; Lott et al., 2006) 
SYNJ1 PtdIns(4,5)P(2) Synaptic dysfunction, 
abnormal vesicle 
trafficking 
Astrogliagenesis 
Learning and 
memory 
deficits  
(Arai et al., 2002; 
Chang and Min, 2009; 
Herrera et al., 2009; 
Voronov et al., 2008) 
Olig2 S100B Increased inhibitory 
neurons 
Increased gliosis 
Decreased IPSC 
 (Chakrabarti et al.; 
Chen et al., 2008; Lu et 
al., 2002; Tatsumi et al., 
2008; Zhou and 
Anderson, 2002) 
Olig1  Increased inhibitory 
neurons 
Decreased IPSC 
 (Chakrabarti et al.; 
Zhou and Anderson, 
2002) 
ITSN1  Synaptic dysfunction, 
abnormal vesicle 
trafficking 
 (Chang and Min, 2009; 
Keating et al., 2006; Yu 
et al., 2008) 
DSCR1 NFAT 
Calcineurin 
Tollip 
ILR1 
Caspase9/3 
Synaptic dysfunction; 
abnormal vesicle 
trafficking, increased 
neuronal susceptibility to 
oxidative stress, neuronal 
apoptosis, mitochondrial 
dysfunction
 (Arron et al., 2006; 
Chang and Min, 2005; 
Keating et al., 2008; Lee 
et al., 2009; Porta et al., 
2007; Sun et al.) 
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HSA21 
genes 
Downstream 
targets 
Endophenotype Exophenotype Ref 
SIM2 Drebrin  Learning and
memory 
impairment, 
reduced 
exploratory 
behavior and 
social 
interactions, 
increased 
tolerance to 
pain
(Chrast et al., 2000; 
Ema et al., 1999; 
Vialard et al., 2000) 
DYRK1A NRSF/REST 
Calcineurin 
CREB 
NFAT 
Tau 
Notch 
P53 
APP 
neuroectodermal 
progenitor, less neuron 
with abnormal branched 
neurites, LTP deficits, 
hyperphosphorylation Tau 
and APP, premature 
neuronal differentiation 
Learning and 
memory 
deficits, motor 
defects 
(Altafaj et al., 2001; 
Arron et al., 2006; 
Canzonetta et al., 2008; 
Fernandez-Martinez et 
al., 2009; Guimera et 
al., 1999; O'Doherty et 
al., 2005; Olson et al., 
2004b; Park et al., 2010; 
Park et al., 2007; Ryoo 
et al., 2007; Sago et al., 
1998; Siarey et al., 2005; 
Smith et al., 1997; 
Woods et al., 2001; 
Yabut et al., 2010; Yang 
et al., 2001) 
KCNJ6 
(GIRK2) 
GABAB Imbalance of excitatory-
inhibitory neuronal 
transmission 
 (Best et al., 2007; 
Cramer et al., 2010; 
Harashima et al., 2006) 
ETS2 APP Increased neuronal 
apoptosis, increased APP 
production, mitochondrial 
dysfunction
 (Helguera et al., 2005; 
Wolvetang et al., 2003a; 
Wolvetang et al., 
2003b)
PCP4 Calmodulin   (Kleerekoper and 
Putkey, 2009; Thomas 
et al., 2003; Utal et al., 
1998)
DSCAM  Overexpression in Purkinje 
cells, cortical neurons and 
senile plaques 
 (Hattori et al., 2007; 
Saito et al., 2000; 
Yamakawa et al., 1998) 
PKNOX1 FABP7   (Sanchez-Font et al., 
2003)
DNMT3L DNMT3A/3B 
HDAC 
Transcription repression   (Deplus et al., 2002; 
Holz-Schietinger and 
Reich, 2010) 
SUMO3 APP 
NRIP1 
ELK 
Inhibit glucocorticoid 
receptors 
 (Dorval et al., 2007; 
Gardiner, 2006; 
Holmstrom et al., 2003) 
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HSA21 
genes 
Downstream 
targets 
Endophenotype Exophenotype Ref 
S100B RAGE 
AQP4 
JNK 
GSK3ß 
Tau 
P53 
ATAD3A 
Increased ROS, 
mitochondrial dysfunction 
and cell death, GSK3ß and 
Tau 
hyperphosphorylation, 
astrocytosis and neurite 
proliferation  
Premature 
neurological 
aging 
(Esposito et al., 2008a; 
Esposito et al., 2008b; 
Gilquin et al., 2010; Lin 
et al., 2001; Mori et al., 
2010; Reeves et al., 
1994) 
Table 1. HSA21 genes implicated in neurodevelopment 
particular DS phenotypes are not known. Several approaches have been used to ascertain 
HSA21 genotype phenotype contributions: analyses of gene clusters based on their physical 
linkage, common function/ interactions and/or temporal-spatial distribution of expression.  
3.1 Structure-based clusters 
Genes that are physically linked based on their location within the same region are usually 
active together and often contribute to the same phenotype. Based on these structure-based 
clusters, comparison of full trisomy 21 and partial trisomy 21 genotypes provide some 
insight between contiguous genes and DS phenotypes. One such region includes APP, 
which is positioned between 27.25 to 27.54Mb on the long arm of HSA21. Five families with 
various segmental trisomies that range from 0.58 to 6.37Mb in length and contain APP were 
all shown to have abundant parenchymal and vascular deposits of beta amyloid without 
MR on brain autopsy, strongly linking APP to AD (Rovelet-Lecrux et al., 2006).  
 
 
Fig. 1. APP is positioned between 27.25 to 27.54Mb on the long arm of HSA21. 
Furthermore, a DS patient with duplication of the distal last 12Mb of HSA21 (a fragment 
that does not include APP) did not develop typical AD pathology (Prasher et al., 1998). 
Recently, Korbel et al. analyzed 30 patients carrying rare segmental trisomies of various 
regions of HSA21 and identified discrete regions between 1.8-16.3Mb in length that were 
likely to be involved in 8 DS CNS and non-CNS phenotypes including MR and AD (Korbel 
et al., 2009). They described a patient with a duplication of 18.8 Mb (28.12-telo) without APP, 
who did not have dementia and had no amyloid accumulation by fMRI. Conversely, several 
patients with segmental trisomies containing APP did show AD characteristics in the 
absence of severe MR, which supports the involvement of APP in AD but not MR. These 
authors were able to narrow down a 1.95Mb interval including APP responsible for the AD 
phenotype, that excludes genes located distal to 28.12 Mb on HSA21q, including BACH1 
and SOD1. These genes were previously suggested to play important roles in the 
development of AD and MR in DS (Ferrando-Miguel et al., 2003; Lott et al., 2006). 
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Collectively, these studies conclude a small-segment containing APP as the basis for AD 
phenotype, with multiple focal regions contributing to MR.   
Through segmental trisomy analyses, the primary features of DS have previously been 
ascribed to the Down syndrome critical region (DSCR). This interval spans about 5Mb around 
21q22.12-q22.2 and contains about 33 conserved genes, including DSCR1 (35.88-35.99 Mb), 
SIM2 (38.07-38.13 Mb), DYRK1A (38.74-38.89), KCNJ6 (38.99-39.29Mb), ETS2 (40.18-40.2Mb), 
PCP4 (41.24-41.3Mb) and DSCAM (41.38-42.22Mb). The contiguous genes are thought to be 
sufficient to replicate the DS features including craniofacial abnormalities, short stature, joint 
hyperlaxity, hypotonia and mental retardation (Delabar et al., 1993; Korenberg, 1990; 
Korenberg, 1993; McCormick et al., 1989; Olson et al., 2004a; Rahmani et al., 1989). Further 
studies suggest that DSCR1 and DYRA1A cooperatively destabilize NFATC and induce DS 
features (Arron et al., 2006; de la Luna and Estivill, 2006). However, several genotype-
phenotype correlation studies argue against this hypothesis, given that other patients with 
partial trisomy 21 that do not include DSCR1, DSCAM or genes within the DSCR have severe 
DS features including MR (Korbel et al., 2009; Lyle et al., 2009; Ronan et al., 2007).  
3.2 Function-based clusters 
Microarray expression profiling and sequencing of the human genome have allowed for 
data analyses and interconnection of functional pathways responsible for various human 
disorders. By comparing differentially expressed genes between normal and pathological 
samples, function-based clusters can be generated and attributed to certain disease 
pathways. We have used this approach in the study of DS human neural progenitors 
(HNPs) at 18 weeks gestation age (Esposito et al., 2008a). Through pairwise comparison of 
mRNA expression levels for approximately 54,000 probes in the HU133 plus 2.0 Affymetrix 
microarray, we observed that some 1900 transcripts (3.8%) were significantly different 
between WT and DS samples, and that these transcripts were distributed across every 
chromosome – not just HSA21. Moreover, of these 1900 transcripts, only 330 transcripts 
(0.07%) were at least 1.5 to 2 fold in excess/deficit on pairwise comparison. These transcripts 
could then be grouped into specific functional networks, including gene clusters involved in 
cell cycle (proliferation), cell compromise (cell death, oxidative stress), cell signalling (stress 
kinases) and cell function and maintenance (differentiation and survival).  For example, 
HSA21 genes such as S100B and amyloid precursor protein (APP) were constitutively over-
expressed in DS HNPs along with various stress related kinases and the water channel 
aquaporin 4 (AQP4). These dysregulated genes comprised a cell signaling functional cluster, 
whereby HSA21 associated S100B and APP led to increased ROS formation, activation of 
stress response kinases, and compensatory AQP4 expression. siRNA inhibition of AQP4 
resulted in elevated levels of ROS following S100B exposure whereas loss of AQP4 
expression led to increased programmed cell death. Results from these studies support the 
hypothesis that HSA21 gene overdose lead to profound disruption of the entire 
transcriptome, but presumably in fairly specific functional groups (FitzPatrick et al., 2002; 
Saran et al., 2003; Tang et al., 2004).  
Using a similar strategy, Bhattacharyya et al. compared the differential expression of genes 
in DS versus WT HNPs at 13 weeks gestation age. Within these earlier aged progenitors, 
they observed similar functional clusters involved in cell death, cell cycle/ proliferation, and 
cell fate/ neuronal development. These studies focused on impairments in interneuron 
neurogenesis, perhaps related to increased expression of gliocentric genes such as Olig1, 
Olig2, OMG and COUP-TF1/NR2F1 and downregulation of the interneuron related genes 
DLX1, DLX2 and DLX5. 
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Fig. 2. Constitutively overexpressed genes on HSA21 (S100B & APP) and AQP4 (shown by 
red arrows) are predicted to form tight interrelationships within known cell signaling 
pathways shown in the networks pooled out from many differentially expressed genes in 
DS HNPs with microarray. 
In another report, Canzonetta used differential expression analyses following microarray 
profiling of normal and trsisomy 21 mouse ES cells and pooled the differentially expressed 
genes into endodermal, mesodermal or ectodermal subgroups. They found reduced 
expression of stem cell genes controlling pluripotency such as Nanog and Sox2; increased 
expression of endodermal genes such as Gata4, Gata6 and Foxa2; increased expression of 
mesodermal genes such as Snail1 and Pitx2 and reduced expression of neuroectodermal 
genes, such as Nestin, Tubb3, Map2 in trisomy 21 ES cells (Canzonetta et al., 2008). More 
pervasively, they observed a decrease in Nrsf/Rest, a key regulator of neuronal 
differentiation and pluripotency. Quantitative linkage analysis (QTL) mapped the REST 
level change to a 3Mb region of HSA21 containing DYRK1A, suggesting that dysregulation 
of this HSA21 gene was an early regulator of various embryonic lineages. 
3.3 Temporal-spatial mapping-based clusters 
Although structure and function cluster approaches provide correlation between DS 
genotype-phenotypes, temporal and spatial distribution of gene expression further refines 
the contribution of individual HSA21 genes in DS neural development and later maturation. 
Previous reports analyzing human trisomy 21 tissue or cells have shown that 
overexpression of different chromosome 21 genes is cell type and developmental time 
specific (Ait Yahya-Graison et al., 2007; Chung et al., 2005; Giannone et al., 2004; Gross et al., 
2002; Li et al., 2006; Lubec and Sohn, 2003; Mao et al., 2005; Mao et al., 2003; Rozovski et al., 
2007). For example, by RNA whole-mount in situ hybridization, gene expression maps of 
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HSA21 orthologues in various aged embryonic or newborn mouse brain have been reported 
(Gitton et al., 2002; Reymond et al., 2002). Of the 158 orthologous genes examined in 
postnatal day 2 mouse brain, 41% were expressed in new cortex, 25% in hippocampus and 
25% in cerebellum. The transcripts expressed in neocortex represent a pool of candidate 
genes for MR of DS, and include DSCAM, SYNJ1 and TIAM1. These genes are implicated in 
synaptic function, axonal guidance, cell migration and neurite outgrowth (Leeuwen et al., 
1997; Saito et al., 2000; Yamakawa et al., 1998).  
While several studies have used human cortical progenitors to identify changes in 
expression profiling, the findings of gene expression levels vary between studies. The 
temporal-spatial variations in DS HNPs may account for these differences.  For example, the 
REST/NRSF transcription factor was previously reported to be selectively repressed in the 
DS HNPs (Bahn et al., 2002). These changes were not seen in our studies or those of others 
(Bhattacharyya et al., 2009; Esposito et al., 2008a). However, this discrepancy could be due to 
the fact that the gestational ages of the euploid and DS fetal tissues used in these differential 
expression studies were not the same.  Similarly, our observations of increased S100B and 
aquaporin 4 levels in 19 week gestational age DS HNPs were not appreciated in 13 week 
gestational age HNPs. This difference would be consistent with the previous notion that 
HNPs mimic normal developmental patterns such that later generated or propagated HNPs 
generate fewer neurons than HNPs harvested at an earlier age. Given that S100B and AQP4 
are associated with more gliocentric phenotypes, upregulation of these genes would be 
expected in later gestational aged HNPs. Similar differences appear to exist with other 
HSA21 genes such as Olig1/2 and DNMT3L (unpublished observations).  
4. Characterization of endophenotypes for AD or MR 
Endophenotypes are pathological changes observed at the histological, cellular or molecular 
levels, which provide an association between candidate genes and the clinical symptoms. 
Clinical neurological symptoms of DS include early onset AD, mental retardation and 
seizures. Histological changes such as increased cell death, gliosis, demyelination, loss in 
neuronal numbers, and gyral simplification are thought to contribute to AD and/or MR in 
DS brain. At the cellular level, DS cells show impairments in mitochondrial function, 
increased levels of oxidative stress, and changes in proliferative rates. An imbalance in 
excitatory-inhibitory neurotransmission, expression changes of genes that affect cell 
fate/differentiation, proliferation/cell cycle and cell injury have been observed at the 
molecular level.  
4.1 Mitochondrial dysfunction and apoptosis 
Oxidative stress is increased in DS brain and the imbalance of reactive oxygen species (ROS) 
metabolism may be the key component giving rise to DS pathogenesis- namely neuronal 
degeneration (Brooksbank and Balazs, 1984; Busciglio and Yankner, 1995). The 
mitochondrial respiratory system is the primary source of ROS, and dysregulation of the 
redox states may induce sequential apoptosis. Several lines of evidence implicate multiple 
HSA21 genes in mitochondrial dysfunction and DS/AD neuropathology. APP is a 
membrane protein associated with neuronal survival and overexpression of APP and its 
products Abeta has been attributed to neurodegeneration in DS and AD (Conti et al., 2010; 
Isacson et al., 2002; Salehi et al., 2006). APP and Abeta are located in mitochondria (Devi and 
Anandatheerthavarada, 2010; Manczak et al., 2006). Abeta peptides induce mitochondrial 
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dysfunction and oxidative stress in astrocytes leading to cell death in neurons (Abramov et 
al., 2004). Impairments in mitochondrial function in astrocytes also alter metabolism and 
secretion of neuroprotective APP and increase neuronal vulnerability (Busciglio et al., 2002). 
Mitochondrial dysfunction, however, does not require aberrant APP and Abeta processing 
specifically. The Ts1Cje DS mouse model, whose partial trisomy 16 does not include the 
APP gene, also exhibits diminished mitochondrial activity (Shukkur et al., 2006). These mice 
show decreased mitochondrial membrane potential and ATP production, increased ROS, 
and increased GSK3ß and JNK/SAPK activities. GSK3ß preserves mitochondrial function, 
and inhibits Ca(2+)-induced mitochondrial permeability (Mio et al., 2009). In addition to 
GSK3ß, several other genes within the Ts1Cje trisomic segment are thought to be involved 
in mitochondrial function. DSCR1 has been reported to be located in the mitochondria and 
to play a critical role in mitochondrial function (Chang and Min, 2005). DYRK1A can 
phosphorylate tau and APP (Park et al., 2007; Woods et al., 2001), and the transcription 
factor ETS-2 increases APP production and promotes the activation of a mitochondrial death 
pathway in DS neurons (Helguera et al., 2005; Wolvetang et al., 2003a; Wolvetang et al., 
2003b). S100B is another HSA21 gene that can increase ROS, it is a calcium binding protein 
that affects calcium-dependent signals, targeting mitochondrial proteins such as p53 and 
ATPase ATAD3A, thereby assisting the cytoplasmic processing of proteins for proper 
folding and subcellular localization. S100B overexpression can also lead to p53 inactivation 
(Donato, 2003; Gilquin et al., 2010; Leclerc et al., 2010; Lin et al., 2001; Mihara et al., 2003). 
Finally, similar mechanisms involving mitochondrial dysfunction have been proposed with 
other HSA21 genes including SOD1 and BATCH1 (Arbuzova et al., 2002; Ferrando-Miguel 
et al., 2003; Furuta et al., 1995; Harris-Cerruti et al., 2004; Iannello et al., 1999; Lott et al., 
2006; Shim et al., 2003). The added, combinatorial effects of these various HSA21 genes in 
oxidative stress, apoptosis in neurons and neuronal progenitors are not known. 
While mitochondrial dysfunction, oxidative stress, and subsequent apoptosis have been well 
appreciated in neurons, only recently changes have been reported in DS HNPs. We have 
shown that upregulation of glial-associated proteins such as S100B lead to tau and GSK3ß 
hyperphosphorylation, suggesting loss of mitochondrial function (Esposito et al., 2008a; 
Esposito et al., 2008b). HNPs over-express the HSA21-localized S100B, leading to increased 
ROS formation such as hydrogen peroxide and nitric oxide, activation of stress response 
kinase pathways (JNK/STAT), and the upregulation of the glial-associated water channel 
AQP4 (Esposito et al., 2008a). This same functional network also predicts an added 
contribution through HSA21 localized APP. Both APP and S100B are upregulated in DS 
HNPs, they reciprocally enhance the expression of one another, have an additive effect on 
increasing hydrogen peroxide, decreasing mitochondrial membrane potential and 
increasing apoptosis (unpublished data). The co-localization of APP and S100B within the 
same HNPs along VZ of cortex may make progenitors even more vulnerable to oxidative 
stress, which is supported by the fact that increased progenitor cell death is seen at nano or 
pico level of S100B or Abeta stimulation (unpublished observations). These same doses are 
neuroprotective in more mature neurons (Lambert et al., 1998; Van Eldik and Wainwright, 
2003; Yankner and Lu, 2009). The additive effects from S100B and APP may depend upon 
their common activation through the extracellular RAGE receptor which has been shown to 
regulate intracellular mitochondrial function (Devi and Anandatheerthavarada, 2010; 
Donato, 2003; Leclerc et al., 2010; Manczak et al., 2006). The in vitro observations from DS 
HNPs are consistent with in vivo observations in polytransgenic mice. S100B/APP double 
transgenic (Tg2576/APP-huS100B) mice display augmented reactive astrocytosis and 
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microgliosis, increased levels of pro-inflammatory cytokines and enhanced apoptosis (Mori 
et al., 2010). The double transgenic (mutant APP (mAPP)/RAGE) mice demonstrate 
increased activation of stress pathways (phosphorylation of p38 and JNK) and altered 
expression of markers of synaptic plasticity (MAP kinases), leading to early abnormalities in 
spatial learning/memory (Arancio et al., 2004).  
4.2 Gliosis and inflammatory changes  
Increased astrocytes and gliosis have previously been reported in DS brain (Guidi et al., 
2008).  Altered redox states and mitochondrial compromise leading to cell death are thought 
to promote these inflammatory changes in mature DS brain (Griffin et al., 1989). In DS the 
increase in the glial marker S100B could be explained, in part, by a gene dosage effect and in 
part by reactive gliosis (Selinfreund et al., 1991).  
A shift in the DS progenitor pool may contribute to the neuronal reduction and increase in 
glial cells within the mature trisomy 21 brain.  Some studies have suggested impairments in 
interneuron neurogenesis within the DS HNP pool, possibly due to over-expression of the 
transcription factor COUP-TF1/NR2F1 (Bhattacharyya et al., 2009). Increased levels of 
COUP-TF1/NR2F1 cause increases in the generation of earlier born neurons and depletion 
of later born interneurons. Alternatively, other reports suggest that HSA21 associated 
DYRK1A causes a skewed ratio of primitive endoderm at the expense of neuroectodermal 
progenitors, leading to a reduction in neurogenesis (Canzonetta et al., 2008). Mensah also 
reported an inhibition of neuroectodermal differentiation in a teratoma model transplanted 
with mouse ES cells injected with HSA21 (Mensah et al., 2007). Our prior studies of DS 
HNPs had demonstrated a constitutive increase in the glial and HSA21 associated S100B 
protein, which in turn, enhanced expression of another glial-associated protein, the water 
channel AQP4. Aquaporins can partially mitigate damage due to ROS, such that glial 
progenitors are more resistant to oxidative damage (Esposito et al., 2008a).  In this setting 
endogenous overexpression of a glial-associated gene S100B might drive gliogenic 
progenitors, while the inflammatory changes from oxidative stressors would further 
promote a gliocentric progenitor pool. Other candidate genes such as HSA21-localized Olig1 
and Olig2 are basic helix-loop-helix (bHLH) transcription factors essential for development 
of oligodendrocytes (Jakovcevski and Zecevic, 2005; Lu et al., 2002; Takebayashi et al., 2002; 
Zhou and Anderson, 2002) or astrocytes (Cai et al., 2007; Marshall et al., 2005; Ono et al., 
2008); and SYNJ1 could increase astrogliosis (Herrera et al., 2009).  The number of 
Olig1/Olig2(+) progenitors increases in the injured CNS (Arnett et al., 2004), and Olig2(+) 
cells preferentially differentiate into GFAP-expressing astrocytes, the main contributors to 
glial scars which further secrete S100B (Chen et al., 2008; Tatsumi et al., 2008). S100B also 
contributes to oligodendrocyte progenitor cells (OPC) differentiation in response to 
demyelinating insults (Deloulme et al., 2004). In addition to transcription factors, epigenetic 
regulation can also control the cell fate changes within progenitors. One possible candidate 
gene in DS is HSA21 associated DNMT3L. DNMT3L is a DNA methyltransferase like gene 
playing a role in DNA methylation by activating DNMT3A or DNMT3B (Jia et al., 2007; Ooi 
et al., 2007; Suetake et al., 2004). It also represses transcription by recruiting histone 
deacetylase (HDAC) (Aapola et al., 2002; Deplus et al., 2002). Hypomethylation in neural 
progenitors leads to precocious astroglial differentiation and perturbed neuronal maturation 
in DNMT1 or DNMT3A knockout mice (Fan et al., 2005; Hutnick et al., 2009), whereas 
HDAC activation increases oligodendrocytes differentiation (Hsieh et al., 2004; Liu et al., 
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2009; Liu and Casaccia, 2010; Shen et al., 2005; Ye et al., 2009). Again the combinatorial 
effects from these various HSA21 genes associated with cell fate changes are not known.  
4.3 Prolonged cell cycle and reduced proliferation 
Proliferation changes during development have been thought to contribute to the decreased 
neuronal numbers and reduced cortical volume in DS brains. Recent studies demonstrated 
impairments in proliferation within both hippocampus and neocortical germinal matrix of 
17 weeks to 21 weeks gestation age fetal DS brains (Contestabile et al., 2007; Guidi et al., 
2008).  The DS progenitor cell cycle is prolonged with more cells remaining in G2 phase, 
thereby causing a reduction in neurogenesis and presumptive increase in astrocytosis. 
Similar endophenotypes are also found in animal models, which show a reduced progenitor 
pool and neurogenesis in ventricular zone or dentate gyrus (Contestabile et al., 2009; 
Haydar et al., 2000; Lorenzi and Reeves, 2006; Moldrich et al., 2009).  The molecular 
mechanisms behind G2 phase prolongation are not known although many genes on HSA21 
can cause proliferation changes.  Overexpression of APP would antagonistically compete 
with the APP-BP1, which is required for the cell cycle progression from G1 to S phase. This 
change would lead to a  predicted slowing in proliferation but at the G1 to S phase (Joo et 
al., 2010). Overexpression of S100B could promote p53 nuclear accumulation and inhibit 
proliferation (Scotto et al., 1999).  Olig2 overexpression has been shown to increase CDK 
inhibitor p27, leading to decreased proliferation (Tabu et al., 2006). Presumably, various 
HSA21 genes may directly act in a combinatorial fashion to affect progenitor proliferation.   
Studies from human DS HNPs raise another potential explanation for altered progenitor 
proliferative rates. Consistent with previous reports, we have also found reduced 
proliferation in HNPs, localized along the ventricular zone of DS cortex, and within DS 
HNPs cultured in vitro. However, characterization of these progenitors have shown that 
these progenitors, while retaining neural progenitor markers, are more gliocentric in their 
expression profile. Some preliminary studies suggest that the DS HNPs have reduced 
voltage gated, outward rectifying potassium channel activity, which correlated to decreased 
proliferation. Increased potassium channel activity has been correlated with increased 
proliferation, whereas decreased channel activity coincides with oligodendrocyte 
differentiation (Chittajallu et al., 2002). Taken in this context, changes in progenitor cell fates 
(due to such HSA21 genes as S100B, APP, and Olig2) may in part explain the reduction in 
cell proliferation. 
4.4 Imbalance of excitatory-inhibitory neurotransmission 
The balance of neurotransmission is important for maintaining normal physiology and 
behavior. Imbalance of excitatory-inhibitory neurotransmission could contribute to the MR 
phenotypes seen in DS. Prior studies have shown decreased excitatory and increased 
inhibitory activities in DS neurons or Trisomy 16 mice. The excitatory neurotransmitter 
glutamate and inhibitory neurotransmitter GABA are both decreased in DS fetal brain 
(Reynolds and Warner, 1988; Risser et al., 1997; Smigielska-Kuzia et al., 2010; Whittle et al., 
2007). Ts65Dn mice show increased inhibitory synapses and decreased excitatory synapses 
in the hippocampus (Belichenko et al., 2009; Belichenko et al., 2004; Kurt et al., 2000; Perez-
Cremades et al., 2010). Excessive GABA inhibition also alters LTP in the hippocampus 
(Costa and Grybko, 2005; Kleschevnikov et al., 2004; Siarey et al., 1997). Likewise, Ts1Cje 
mice show a shortened long term potentiation and an increase in long term depression, as 
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well as a decrease in the evoked field excitatory postsynaptic potentials- all consistent with 
impairments in short and long term plasticity (Siarey et al., 2005).  
Various HSA21 genes could theoretically affect synaptic function and thereby alter memory 
and learning. TINM1, SYNJ1 and ITSN1 are thought to play some role in synaptic plasticity, 
KCNJ6, KCNJ15, KCNE1 and KCNE2 would alter channel activity, whereas NRIP1, ETS2, 
PCP4, DSCR1, DYRK1A, S100B and APP have some role in affecting neurotransmitter 
receptors or intracellular signaling. Another more closely scrutinized HSA21 gene GIRK2 
(KCNJ6), an inwardly rectifying K channel, could contribute to synaptic inhibition. GIRK2 
channels are overexpressed in Ts65Dn hippocampus and frontal cortex (Harashima et al., 
2006). The overexpression leads to a significant increase in GABAB-mediated GIRK current 
in primary cultured hippocampal neurons, and likely affects the balance between excitatory 
and inhibitory neuronal transmission (Best et al., 2007). Pharmacological treatment of the 
trisomy 16 mice with GABAA antagonists at non-epileptic doses causes a persistent post-
drug recovery of cognition and LTP (Fernandez et al., 2007). Interestingly, treatment of these 
same mice with the uncompetitive NMDAR antagonist memantine rescues the performance 
deficits on a fear-conditioning test (Costa et al., 2008). Memantine mimics calcineurin action 
and the HSA21 DSCR1 gene inhibits calcineurin activity. This raises the hypothesis that 
DSCR1 overexpression produces a pathological increase in NMDAR activity.  
Earlier developmental changes in DS HNPs could also contribute to the imbalance of 
excitatory and inhibitory neurotransmission. Alterations in cell fate through genes such as 
Olig1 and Olig2 could lead to an abnormal ratio or distribution of excitatory and inhibitory 
neurons. Overexpression of HSA21 located Olig1 and Olig2 have been shown to increase 
GABAergic interneuron neurogenesis in Ts65Dn mice, and the dysregulation of excitatory-
inhibitory imbalance could be rescued by knocking down the extra copy of these two genes 
(Chakrabarti et al., 2010). This phenotype contrasts with our observations and those from 
other groups, who have observed a reduction of interneurons in DS HNPs at the expense of 
increasing oligodendrocytes (Bhattacharyya et al., 2009). We see a shift from neuronal to 
gliocentric progenitors with overexpression of S100B (Esposito et al., 2008a) and APP 
(unpublished observations), which would potentially further compromise the interneuron 
population.  This decline in interneuron neuronal production is consistent with the loss in 
GABA-ergic interneurons, as opposed to total neuronal numbers, reported in the DS cortex, 
further reiterating differences between the mouse and human disorders (Golden and 
Hyman, 1994; Ross et al., 1984; Weitzdoerfer et al., 2001). 
5. Combinatorial gene effects in DS HNPs contribute to the DS phenotype  
HSA21 associated genes which are implicated in cell death and oxidative stress could 
contribute to the later endophenotypes seen in DS. To identify functional modules of gene 
expression and interacting partners relevant to DS HNPs, we had applied network-based 
analyses through the Ingenuity Pathways Knowledge Base (IPA) (Calvano et al., 2005). 
Among 1902 genes that were significantly different on pairwise comparison between WT-
DS expression profiling of HNPs, 334 genes were shown to interact within 46 functional 
networks (Esposito et al., 2008a). The top four interactive networks incorporated 93 
dysregulated genes involved in cell cycle, cell death, oxidative stress and several canonical 
signal transduction pathways. These findings would suggest that genes involved in these 
primary functional clusters might later contribute to the observed DS endophenotypes.  
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To understand the role of HSA21 genes in progenitor cell death and changes in redox state, 
we first focused on HSA21 genes APP and S100B. These molecules were included in one of 
the top functional clusters and were associated with other cell signaling molecules, 
including JAK/STAT and MAPK, which have been implicated in the stress response 
pathway, inflammation and potentially gliosis. Using this potential pathway, we found that 
upregulation of S100B activated the JAK/STAT MAPK pathway through the RAGE 
receptor. RAGE receptor activation induced mitochondrial disruption and oxidative stress. 
Activation of this pathway enhanced progenitor cell death and likely gliosis, as suggested 
by increased expression of glial associated water channel AQP4 (Esposito et al., 2008a). We 
have also been able to observe a S100B-mediated induction of tau protein 
hyperphosphorylation via Dickopff-1 up-regulation and disruption of the Wnt pathway, 
suggesting a shared common final pathway with APP (Esposito et al., 2008b).  
Although APP and S100B have previously been implicated in oxidative stress and cell death, 
constitutive over-expression of these and other HSA21 genes would also predict 
upregulation of inflammatory responses (astrocytosis), leading to a skewed gliocentric 
progenitor phenotype.  The ongoing cell death and inflammation from APP and S100B 
promote reactive astrocytosis and astrocytes secrete S100B, causing further cell injury and 
death (Li et al., 2011). This same mechanism of injury in the mature brain could also take 
place within the progenitor population during development. Additionally, the transcription 
factors Olig1/2 increase oligodendroglial progenitor numbers and would likely augment any 
gliocentric shift. Similarly, the HSA21 DNA methylthansferase like DNMT3L gene recruits 
HDACs, which compete with beta catenin to regulate TCF4 dependent transcriptional 
inhibition of neuronal progenitor proliferation and activation of oligoprogenitor phenotypes 
(Aapola et al., 2002; Deplus et al., 2002; Liu et al., 2009; Ye et al., 2009).   
A gliocentric shift in the progenitor pool could alter rates of proliferation and create an 
imbalance in excitatory-inhibitory transmission. Gliocentric progenitors would be predicted 
to demonstrate reduced voltage gated, outward rectifying potassium channel activity, and 
consequent slower rates of proliferation. Moreover, the ongoing neural progenitor cell death 
from oxidative stress enhances gliocentric progenitor characteristics at the expense of 
neuronal progenitor phenotypes. This shift becomes more prominent later in cortical 
development when the cyclical and synergistic roles played by such inflammatory 
mediators such as S100B and APP become more pronounced. Under this paradigm, the loss 
in neuronogenic progenitors would manifest later in development and thereby affect 
interneuron production. 
These observations raise a hypothetical paradigm whereby several specific HSA21-localized 
genes promote a deleterious, cyclical pathway involving ROS, hypersecretion of S100B, APP 
overproduction and proliferation of gliocentric progenitors. A gliocentric shift in the 
progenitor pool would provide a potential explanation for the predominant 
endophenotypes seen in the DS brain.  
6. Pharmacological approach using DS HNPs 
From a translational standpoint, human neurally-derived reagents will be useful to identify 
pathological mechanisms and address the efficacy of pharmacotherapeutics. Given that DS 
is a contiguous gene syndrome, multiple genes on HSA21 will interact, share substrates, 
and/or influence the same processes or pathways relevant to neural function. Our ongoing 
work demonstrates that some genes such as S100B and APP are over-expressed from 
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development into adulthood and would therefore have potentially cumulative effects over 
time. In this respect, treatment directed toward correcting aberrant pathways regulated by 
these genes may require early and ongoing management to achieve efficacy.  Other genes 
which might also contribute to gliocentric phenotypes and which reside on HSA21 such as 
Olig1/2 appear to be more temporally restricted (personal observations, Lu and Sheen) and 
therefore might be more amenable to a finite pharmacological approach. It remains to be 
seen to what extent the observations made from various treatment modalities for trisomy 
mouse models and/or DS HNPs are faithfully replicated in actual individuals with DS. That 
said, the use of DS HNPs would provide another measure of validation for 
pharmocotherapies devised in treatment of these disorders. 
7. Conclusion 
DS is a contiguous gene syndrome giving rise to MR, dementia, and seizures. These clinical 
outcomes are mirrored by endophenotypes including mitochondrial dysfunction, oxidative 
stress, cell death, gliosis, inflammation, prolonged cell cycle, reduction in proliferation and 
imbalances in excitatory and inhibitory neurotransmission. While these characteristics have 
largely been observed in neurons in the mature brain, function based cluster analyses of 
pair-wise comparisons between normal and DS human neural progenitors suggest that 
similar changes are ongoing during development. Moreover, these endophenotypes likely 
arise from the integration of various genetic and epigenetic factors on chromosome 21 such 
as APP, S100B, Olig1/2 and DNMT3L. The ongoing disruption of mitochondrial redux 
states and inflammation promote early gliocentric phenotypes in the progenitor pool, which 
would alter progenitor proliferative rates and contribute to a decline in interneuron 
production. Overall, early developmental changes in the progenitor population could 
promote many of the deleterious changes seen later in the mature DS brain. 
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